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ABSTRACT		Tedizolid	Phosphate	is	an	oxazolidinone-class	antibiotic	and	is	used	for	the	treatment	of	acute	bacterial	skin	and	skin	structure	infections.	it	is	a	prodrug	activated	by	plasma	or	intestinal	phosphatases	to	tedizolid	fol-lowing	administration	of	the	drug	either	orally	or	intravenously.	Once	activated,	tedizolid	exerts	its	bacteri-ostatic	microbial	activity	through	inhibition	of	protein	synthesis	by	binding	to	the	50S	ribosomal	subunit	of	the	bacteria.	The	purpose	of	the	study	was	to	evaluate	safety	and	efficacy	of	Tedizolid	phosphate	and	com-pare	it	with	that	of	Lenizolid	Phosphate	another	oxazolidinone	class	of	drugs.	The	study	was	conducted	at	OMNI	hospital	located	at	dilsukhnagar,	Hyderabad.	126	subjects	with	skin	infections,	who	satisfied	the	eli-gibility	criteria,	were	accrued	during	the	study	period.	These	patients	were	randomized	into	2	groups,	and	were	then	evaluated	according	to	the	treatment	protocol.	Investigational	product	was	then	administered	to	evaluate	safety	and	efficacy	parameters.	Subjects	 received	 treatment	according	 to	 the	study	arm/group.	Subjects	were	asked	to	take	drug	for	7	days	daily	once	orally	till	the	clinical	symptoms	disappear/	as	per	PIs	discretion.	Samples	for	microbiological	evaluation	were	done	at	screening,	end	of	the	therapy.	Among	both	the	formulations	the	group	the	received	Tedizolid	phosphate	was	considered	safer	and	more	efficacious	as	Clinical	success	rate	was	89.9%	and	the	group	that	received	Lenizolid	phosphate	had	the	clinical	success	rate	of	81%.	It	can	be	concluded	that	Tedizolid	phosphate	could	be	promising	drug	in	the	treatment	of	var-ious	skin	infections.	 	 	
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INTRODUCTION	Infection	is	the	invasion	of	a	host	organism's	body	tis-sues	by	disease-causing	agents,	 their	multiplication,	and	 the	 reaction	of	 host	 tissues	 to	 these	organisms	and	 the	 toxins	 they	 produce[1].	 Infectious	 diseases,	also	known	as	transmissible	diseases	or	communica-ble	diseases,	 comprise	clinically	evident	 illness	 (i.e.,	characteristic	medical	signs	and/or	symptoms	of	dis-ease)	 resulting	 from	 the	 infection,	 presence	 and	growth	of	pathogenic	biological	agents	in	an	individ-ual	host	organism.	Bacterial	 skin	 infections	 may	 be	 uncomplicated	 or	complicated.	 Uncomplicated	 infections	 usually	 re-spond	 promptly	 to	 systemic	 antibiotics	 and	 local	wound	 care.	 A	 skin	 infection	 is	 considered	 compli-cated	when	it	meets	2	of	the	following	5	criteria:	Involves	a	preexisting	wound	or	ulceration	of	the	skin	Involves	the	deeper	soft	tissues	Requires	surgical	intervention	
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Is	caused	or	exacerbated	by	underlying	comorbid	dis-ease	states	 (eg,	diabetes,	 systemic	 immunosuppres-sion)	Is	unresponsive	to	conventional	antibiotic	therapy	or	is	recurrent	All	uncomplicated	skin	infections	have	the	potential	to	 become	 complicated.	 Complicated	 skin	 and	 soft-tissue	infections	may	require	multidrug	therapy	and	the	assistance	of	other	consultants	(eg,	surgeons,	in-fectious	disease	specialists),	particularly	in	light	of	re-sistance	in	many	strains	of	bacteria	and	the	rapid	loss	of	efficacy	among	more	potent	antibiotics.	Recurrent	skin	infections	should	raise	suspicion	of	colonization	(eg,	 staphylococcal	nasal	 carriage),	 resistant	 strains	of	 bacteria	 (eg,	methicillin-resistant	 Staphylococcus	aureus	(MRSA),	cancer,	poorly	controlled	diabetes,	or	other	reasons	for	immunocompromise	(eg,	HIV,	hep-atitis,	advanced	age,	congenital	susceptibility).	Bacte-ria	are	 involved	in	the	pathophysiology	of	acne,	but	acne	is	not	primarily	considered	a	bacterial	skin	in-fection.	
Types	of	acute	bacterial	skin	infections	
Cellulitis:	Cellulitis	is	acute	bacterial	infection	of	the	skin	and	subcutaneous	 tissue	most	often	 caused	by	streptococci	 or	 staphylococci.	 Symptoms	 and	 signs	are	pain,	rapidly	spreading	erythema,	and	edema;	fe-ver	may	 occur,	 and	 regional	 lymph	 nodes	may	 en-large[2].	 Diagnosis	 is	 by	 appearance;	 cultures	 are	sometimes	helpful,	but	awaiting	these	results	should	not	delay	empiric	therapy.	Treatment	is	with	antibi-otics.	 Prognosis	 is	 excellent	 with	 timely	 treatment.	Cellulitis	isn't	usually	spread	from	person	to	person.	Cellulitis	 is	 an	 infection	 of	 the	 deeper	 layers	 of	 the	skin	 most	 commonly	 caused	 by	 bacteria	 that	 nor-mally	live	on	the	skin's	surface.	Have	an	injury,	such	as	a	cut,	fracture,	burn	or	scrape		Cellulitis	 is	 typically	 unilateral;	 stasis	 dermatitis	closely	mimics	cellulitis	but	 is	usually	bilateral.	The	major	 findings	 are	 local	 erythema	 and	 tenderness,	frequently	with	lymphangitis	and	regional	lymphad-enopathy.	The	skin	is	hot,	red,	and	edematous,	often	with	surface	appearance	resembling	the	skin	of	an	or-ange	(peaud’orange).	The	borders	are	usually	indis-tinct,	 except	 in	 erysipelas.	 Petechiae	 are	 common;	large	areas	of	ecchymosis	are	rare.	Vesicles	and	bul-lae	may	develop	and	 rupture,	 occasionally	with	ne-crosis	of	the	involved	skin.	Cellulitis	may	mimic	deep	venous	thrombosis	but	can	often	be	differentiated	by	one	or	more	features.	Fever,	chills,	tachycardia,	head-ache,	hypotension,	and	delirium	may	precede	cutane-ous	findings	by	several	hours,	but	many	patients	do	not	appear	ill.	Leukocytosis	is	common.	Cellulitis	with	rapid	spread	of	infection,	rapidly	increasing	pain,	hy-potension,	 delirium,	 or	 skin	 sloughing,	 particularly	with	bullae	 and	 fevers,	 suggests	 life-threatening	 in-fection.	Following	may	have	the	occurrence	of	celluli-tis	
Have	a	skin	condition,	such	as	eczema,	athlete's	foot	or	shingles	Participate	in	contact	sports,	such	as	wrestling	Have	diabetes	or	a	weakened	immune	system	Have	 a	 chronic	 swelling	 of	 your	 arms	 or	legs(lymphedema)	Use	intravenous	drugs	
Skin	abscess	causes:	A	skin	abscess	is	a	build	up	of	pus	 in	 or	 on	 the	 skin.	 Skin	 abscesses	 are	 typically	caused	by	either	an	inflammatory	reaction	to	an	in-fectious	process	 (bacteria	or	parasite)	or,	 less	com-monly,	to	a	foreign	substance	within	the	body(a	nee-dle	 or	 a	 splinter,	 for	 example).	 Abscesses	 may	 de-velop	because	of	obstructed	oil(sebaceous)	or	sweat	glands,	inflammation	of	hair	follicles,	or	from	minor	breaks	 and	 punctures	 of	 the	 skin[7].	 Abscesses	may	also	develop	after	a	surgical	procedure.	The	infectious	organisms	or	foreign	material	cause	an	inflammatory	 response	 in	 the	 body,	 which	 triggers	the	body's	immune	system	to	form	a	cavity	or	capsule	to	contain	the	infection	and	prevent	it	from	spreading	to	other	parts	of	 the	body[8].	The	 interior	of	 the	ab-scess	 liquefies,	 and	 pus	 develops	 (which	 contains	dead	cells,	proteins,	bacteria,	and	other	debris).	This	area	then	begins	to	expand,	creating	increasing	ten-sion	and	inflammation	of	the	overlying	skin.	
Internal	 abscesses:	Abscesses	 that	 develop	 inside	the	 tummy	 (abdomen)	 are	 caused	 by	 an	 infection	reaching	tissue	deeper	within	the	body.	This	can	oc-cur	as	a	result	of:	an	injury	abdominal	surgery	an	infection	spreading	from	a	nearby	area	There	are	many	ways	an	infection	can	spread	into	the	abdomen	and	cause	an	abscess	to	develop.	For	exam-ple,	a	lung	abscess	can	occur	due	to	a	bacterial	infec-tion	in	your	lungs,	such	as	pneumonia,	and	a	burst	ap-pendix	can	spread	bacteria	within	abdomen.	
Infected	 wound:	 Infected	 wounds	 are	 wounds	 in	which	bacteria	 or	 other	microorganisms	have	 colo-nized,	causing	either	a	delay	in	wound	healing	or	de-terioration	of	the	wound.	Most	wounds	are	typically	contaminated	 by	 bacteria[9].	 However,	 infected	wounds	result	when	the	body's	immune	defenses	are	overwhelmed	or	cannot	cope	with	normal	bacterial	growth.	 Infection	of	wounds	caused	by	surgery	 is	a	serious	 health	 risk,	 as	 studies	 have	 shown	 that	 70	percent	of	the	deaths	of	patients	who	have	undergone	surgery	are	caused	by	surgical	site	infections	
Risk	for	a	wound	infection	This	includes	any	of	the	following:	Diseases	such	as	diabetes,	cancer,	or	liver,	kidney	or	lung	conditions	slow	healing.	
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Foreign	objects	such	as	glass	or	metal	can	get	stuck	in	the	wound	and	delay	healing.	Poor	blood	supply	to	the	wound	increases	your	risk	for	 infection.	Blood	 flow	may	be	decreased	by	high	blood	pressure,	and	blocked	or	narrowed	blood	ves-sels.	 Your	 risk	 also	 increases	 if	 you	 smoke,	 or	have	blood	vessel	problems	or	a	heart	condition	Repeated	 trauma	 to	 a	 healing	wound	may	 increase	your	risk	for	an	infection,	and	delay	healing.	A	weak	immune	system	caused	by	radiation,	poor	nu-trition,	or	certain	medicines	increases	your	risk	for	an	infection.	
Causative	organism	
MRSA:	 Methicillin-resistant	 Staphylococcus	 aureus	(MRSA)	is	a	bacteria	that	is	resistant	to	many	antibi-otics.	 In	 the	 community,	 most	MRSA	 infections	 are	skin	infections.	In	medical	facilities,	MRSA	causes	life-threatening	bloodstream	infections,	pneumonia	and	surgical	site	infections.	MRSA,	 also	 called	methicillin-resistant	 Staphylococ-cusaureus	or	multiple-resistant,	bacterium	in	the	ge-nus	 Staphylococcus	 that	 is	 characterized	 by	 its	 re-sistance	 to	 the	 antibiotic	methicillin	 and	 to	 related	semisynthetic	 penicillins.	MRSA	 is	 a	 strain	 of	 S.	 au-reus	and	was	first	isolated	in	the	early	1960s,	shortly	after	methicillin	 came	 into	use	as	an	antibiotic.	Alt-hough	methicillin	 is	 no	 longer	 used,	 MRSA	 has	 be-come	widespread	some	50	million	people	worldwide	are	believed	to	carry	the	organism	It	is	commonly	found	on	the	skin,	in	the	nose,	or	in	the	blood	or	urine.	Most	MRSA	infections	occur	in	people	who've	been	in	hospitals	or	other	health	care	settings,	such	as	nursing	homes	and	dialysis	centers.	When	it	occurs	in	these	settings,	it's	known	as	health	care-as-sociated	 MRSA	 (HA-MRSA)[12].	 HA-MRSA	 infections	typically	are	associated	with	invasive	procedures	or	devices,	such	as	surgeries,	intravenous	tubing	or	arti-ficial	joints.	Another	type	of	MRSA	infection	has	occurred	in	the	wider	community	among	healthy	people.	This	form,	community-associated	 MRSA(CA-MRSA),	 often	 be-gins	as	a	painful	skin	boil.	It's	spread	by	skin-to-skin	contact.	 At-risk	 populations	 include	 groups	 such	 as	high	school	wrestlers,	child	care	workers	and	people	who	live	in	crowded	conditions.	Doctors	diagnose	MRSA	by	checking	a	tissue	sample	or	nasal	secretions	for	signs	of	drug-resistant	bacte-ria.	The	sample	is	sent	to	a	lab	where	it's	placed	in	a	dish	of	nutrients	that	encourage	bacterial	growth.	But	because	 it	 takes	 about	 48	hours	 for	 the	 bacteria	 to	grow,	newer	tests	that	can	detect	staph	DNA	in	a	mat-ter	of	hours	are	now	becoming	more	widely	available.	
Staphylococcous	The	organism	may	cause	disease	through	tissue	inva-sion	and	toxin	production.	The	toxins	liberated	by	the	organism	may	have	effects	at	 sites	distant	 from	the	
focus	of	infection	or	colonization.	The	postulated	se-quence	 of	 events	 that	 leads	 to	 infection	 is	 initiated	with	carriage	of	the	organism.	The	organism	is	then	disseminated	via	hand	carriage	to	body	sites	where	infection	may	occur	(either	through	overt	breaks	 in	dermal	surfaces,	such	as	vascular	catheterization	or	operative	 incisions,	 or	 through	 less	 evident	 break-down	in	barrier	function,	such	as	eczema	or	shaving-associated	microtrauma).	The	 hallmark	 of	 staphylococcal	 infection	 is	 the	 ab-scess,	which	consists	of	a	 fibrin	wall	surrounded	by	inflamed	tissues	enclosing	a	central	core	of	pus	con-taining	organisms	and	leukocytes.	From	this	focus	of	infection,	the	organisms	may	be	disseminated	hema-togenously,	even	from	the	smallest	abscess.	The	abil-ity	 to	 elaborate	 proteolytic	 enzymes	 facilitates	 the	process[13].This	 may	 result	 inpneumonia,	 bone	 and	joint	infection,	and	infection	of	the	heart	valves.	In	im-munocompromised	 hosts	 (eg,	 patients	 with	 cancer	who	are	neutropenic	and	have	a	central	venous	line),	20-30%	develop	serious	complications	or	fatal	sepsis	following	catheter-related	S	aureus	bacteremia.	Persistent	 deep-seated	 infections	 have	 now	 been	linked	to	small-colony	variants	of	the	organism.	This	population	is	more	resistant	to	antibiotics	and	grows	slowly.	These	organisms	have	been	described	in	pa-tients	with	cystic	fibrosis	and	may	contribute	to	the	persistence	of	S	aureus	in	these	patients.	S.	aureus	has	long	been	recognized	as	one	of	the	most	important	bacteria	that	cause	disease	in	humans.	It	is	the	 leading	 cause	 of	 skin	 and	 soft	 tissue	 infections	such	as	abscesses(boils),	furuncles,	and	cellulitis.	Alt-hough	most	staph	infections	are	not	serious,	S.	aureus	can	cause	serious	infections	such	as	bloodstream	in-fections,	pneumonia,	or	bone	and	joint	infections.	Staphylococcus	aureus	belongs	to	the	family	Staphy-lococcaceae.	It	affects	all	known	mammalian	species,	including	humans.	Further	due	to	its	ability	to	affect	a	wide	range	of	species,	S.	aureus	can	be	readily	trans-mitted	 from	 one	 species	 to	 another.	 This	 includes	transmission	between	humans	and	animals.	
Variety	of	manifestations	s.	Aureus	may	cause	Minor	skin	infections,	such	as	pimples,	impetigo	etc.	It	 may	 cause	 boils(furuncles),	 cellulitis	 folliculitis,	carbuncles	It	 is	 the	 cause	 of	 scalded	 skin	 syndrome	 and	 ab-scesses	It	may	lead	to	lung	infections	or	pneumonia	Brain	infections	or	meningitis	Bone	infections	or	osteomyelitis	Heart	infections	or	endocarditis	Generalized	life	threatening	blood	infections	or	Toxic	shock	syndrome	(TSS),	bacteremia	and	septicaemia	
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Types	and	presentation	of	s	aureus	infection	in-
clude	the	following	
Impetigo:	A	small	area	of	erythema	that	progresses	into	bullae	(filled	with	cloudy	fluid)	that	rupture	and	heal	with	the	formation	of	a	honey-colored	crust	
Scalded	 skin	 syndrome	 (ritter	 disease):	 A	 rela-tively	rare,	toxin-mediated	disorder	with	superficial	fragile	blisters	that	burst,	leaving	a	tender	base;	often	accompanied	by	fever	and	occasionally	by	mucopuru-lent	eye	discharge	
Folliculitis:	A	 tender	pustule	 that	 involves	 the	hair	follicle	
Furuncle:	Small	abscesses	characterized	by	exuding	purulent	 material	 from	 a	 single	 opening;	 involves	both	the	skin	and	the	subcutaneous	tissues	in	areas	with	hair	follicles	
Carbuncle:	 An	 aggregate	 of	 connected	 furuncles,	with	several	pustular	openings	
Bone	 infections(osteomyelitis):	 In	 children,	 sud-den	 onset	 of	 fever	 and	 bony	 tenderness	 or	 a	 limp;	pain	may	be	throbbing	and	severe;	however,	presen-tation	in	neonates	can	be	subtle	
Septic	arthritis:	Decreased	range	of	motion,	warmth,	erythema,	and	tenderness	of	the	joint	with	constitu-tional	symptoms	and	fever;	however,	these	signs	may	be	absent	in	infants	(in	whom	the	hip	is	the	most	com-monly	involved	joint)	
Endocarditis:	Initially	presents	as	fever	and	malaise;	peripheral	 emboli	 may	 be	 present;	 may	 involve	healthy	valves	
Toxic	shock	syndrome:	Fever,	diffuse	macular	ery-thema,	 and	 hypotension,	 with	 involvement	 of	 3	 or	more	 organ	 systems;	 can	 be	 rapidly	 progressive	 in	previously	healthy	individuals	
Pneumonia:	Most	 common	 in	 infants,	 young	 chil-dren,	and	debilitated	patients;	a	short	prodrome	of	fe-ver	 followed	by	 rapid	onset	of	 respiratory	distress;	prominent	GI	symptoms	may	also	occur	
Thrombophlebitis:	Fever,	pain,	and	occasionally	er-ythema	at	the	insertion	site	of	an	intravenous	cathe-ter;	usually	affects	hospitalized	patients	
Deep	tissue	abscess	and	infection:	Muscles	and	or-gans	 can	 become	 infected,	 including	 the	 parotid	gland,	eyes,	 liver,	spleen,	kidneys,	and	central	nerv-ous	 system;	 deep	 abscesses	 also	 may	 occur;	 fever	with	or	without	localizing	pain	is	typical	
MATERIALS	AND	METHODS	
Factors	to	be	identified:	Efficacy	and	safety	within	finished	population.	
Data	focus:	Efficacy,	Adverse	events		
Design	 features:	 Randomized,	 Controlled,	 2	 treat-ment	arms,	interventional	
Study	duration:	3	months		
Population:	Individuals	with	target	disease	
Sample	size:	126	Patients	with	proven	arthritis.	
• The	study	was	conducted	in	omni	hospital,	Hy-derabad.	
• 126	patients,	who	satisfied	 the	eligibility	crite-ria,	were	accrued	during	the	study	period.	
• These	 patients	 were	 randomized	 into	 2-Arms,	and	were	then	evaluated	according	to	the	treat-ment	protocol.	
Inclusion	criteria	
• Males	or	females	>/=18	years	old	
• Adequate	venous	access	for	a	minimum	of	2	I.V.	doses	of	study	drug	
• Acute	Bacterial	Skin	and	skin	structure	infection	(ABSSSI)	meeting	at	 least	1	of	 the	clinical	 syn-drome	definitions	listed	below	and	requiring	I.V.	antibiotic	 therapy.	 Local	 symptoms	must	 have	started	within	7	days	before	the	Screening	Visit	
• Cellulitis/erysipelas	
• Major	cutaneous	abscess	
• Wound	Infection	
• Suspected	 or	 documented	 gram-positive	 infec-tion	from	baseline	Gram	stain	or	culture.	
Exclusion	criteria	
• Uncomplicated	 skin	 and	 skin	 structure	 infec-tions	such	as	furuncles,	minor	abscesses	
• Infections	associated	with,	or	in	close	proximity	to,	a	prosthetic	device	
• Severe	sepsis	or	septic	shock	
• Known	bacteremia	at	time	of	screening	
• ABSSSI	due	to	or	associated	with	any	of	the	fol-lowing:	
• Suspected	or	documented	gram-negative	patho-gens	in	patients	with	cellulitis/erysipelas	or	ma-jor	cutaneous	abscess	that	require	an	antibiotic	with	 specific	 gram-negative	 coverage.	 Patients	with	wound	infections	where	gram-negative	ad-junctive	therapy	is	warranted	may	be	enrolled	if	they	meet	the	other	eligibility	criteria	
• Diabetic	 foot	 infections,	 gangrene,	 or	 perianal	abscess	
• Concomitant	infection	at	another	site	not	includ-ing	a	secondary	ABSSSI	lesion	(eg,	septic	arthri-tis,	endocarditis,	osteomyelitis)	
• Infected	burns	
• Decubitus	or	chronic	skin	ulcer,	or	ischemic	ul-cer	due	to	peripheral	vascular	disease	(arterial	or	venous)	
• Any	 evolving	 necrotizing	 process	 (ie,	 necrotiz-ing	fasciitis)	
Use	of	antibiotics	as	follows	
• Systemic	antibiotic	with	gram-positive	cocci	ac-tivity	 for	 the	 treatment	of	any	 infection	within	24	hours	before	the	first	infusion	of	study	drug	
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• Patients	 who	 failed	 prior	 therapy	 for	 the	 pri-mary	 infection	 site	 are	 also	 excluded	 from	en-rollment	
• Topical	antibiotic	on	the	primary	 lesion	within	24	hours	before	the	first	infusion	of	study	drug	except	for	antibiotic/antiseptic-coated	dressing	applied	to	the	clean	postsurgical	wound	
• Administration	of	Linezolid	within	30	days	be-fore	the	first	infusion	of	the	study	drug	
• Recent	history	of	opportunistic	infections	where	the	underlying	cause	of	 these	 infections	 is	 still	active	(eg,	leukemia,	transplant,	acquired	immu-nodeficiency	syndrome	(AIDS))	
• Previous	exposure	to	Tedizolid	Phosphate	treat-ment	
Patient	history		
• A	detailed	history	has	been	ascertained	and	en-tered	in	the	CRF.	
• A	detailed	previous	history	has	been	recorded.	
• Past	history	of	taking	any	drugs,	antibiotics	and	any	history	of	previous	hospitalization,	 associ-ated	 illness	 and	 habits	 and	 diet	 has	 been	 rec-orded	in	detail.	
• Any	significant	family	history	was	also	recorded.		
Patient	screening	procedure	includes	
• Demography	
• Medical	history	
• Prior	medication	
• Physical	examination	
Vital	 signs:	Blood	 pressure,	 pulse,	 respiratory	 rate	and	oral	temperature,	BMI	determination	
Urine	 pregnancy	 test	 (UPT):	 Only	 for	 females	 of	child	bearing	potential,	Blood	culture	
Demographic	
• All	the	patients	who	met	the	study	criteria	were	enrolled	in	the	study	&	reviewed	daily.		
• Name,	Age	and	Sex	of	patients,	hospital	register	number,	
Sample	collection	methodology	
Laboratory	Investigation	
• Complete	Blood	Count	
• Microbiological	Culture	processes	
• Blood	Culture	
Sample	Collection	Procedures	
Blood	sample	collection	
Vein	Puncture	
• Usually	prefer	the	upper	arm	
• Primary	vein:	median	cubital	vein	
• Secondary	Vein:	Cephalic	vein	
• Tertiary	Vein:	Basilic	vein	
Torniquete	Application		
• Assist	in	feeling	good	vein		
• Tied	three	to	four	inch	above	the	site	of	punc-ture	
• Should	 not	 use	 more	 than	 one	 minute	 to	avoid	hemoconcentration	
• Should	be	removed	before	removal	needle.	
Cleaning	of	puncture	site	It	should	be	done	by	alcohol	swab	in	circular	motion	inside	and	outside	 to	prevent	 contamination	of	 site	and	specimen.	Let	the	site	to	dry	for	a	minute	
Specimen	Labelling	Fell	the	requisition	form	which	should	be	for	each	in-dividual	patient	Label	with	sticker	by	writing	requisition	no,	subject	ID	for	the	maintenance	of	lab	records.	
Sample	Containers	
SST	Tube:	(Yellow	top),	Specimen	withdrawn=	5ml	
Processing		
• Invert	the	SST	tube	gently	five	times	
• Allow	blood	in	SST	tube	to	clot	upright	at	room	temp	for	30-60	minutes	(Don’t	allow	the	tubes	to	sit	longer	than	one	hour	after	collection)	
• Centrifuge	SST	tube	for	10-15	minutes	at	1250	RCF.	 Carefully	 remove	 tube	 from	 centrifuge	and	maintain	it	in	upright	position.	
• Transfer	separated	serum	to	serum	tube	(yel-low	cap)	using	disposable	transfer	pipette.	
• Storage:	Store	serum	tube	at	 room	tempera-ture	(250C	or	lower)	
Administration	of	investigational	product:	After	signing	the	informed	consent,	study	related	pro-cedures	blood	sampling	for	microbial	testing	and	sen-sitivity	is	carried	out.	Subject	will	be	randomized	to	receive	empiric	therapy	with	the	study	drugs	on	the	same	day	of	screening.		Once	subjects	meet	the	eligibility	criteria,	they	will	be	continued	in	the	study.		Subjects	will	receive	drug	treatment	according	to	the	study	 arm/group.	 Subjects	 are	 asked	 to	 administer	drug	for	7	days	daily	once	orally	till	the	clinical	symp-toms	 disappear/	 as	 per	 PIs	 discretion.	 Samples	 for	microbiological	evaluation	will	be	done	at	screening,	end	of	the	therapy.	
RESULTS	AND	DISCUSSION	
Table 1: Demographic variables 
Demographic 
baseline charac-
ters 
Group(n=63) Group(n=63) 
Age (yrs) (mean) 37.3 (12.1) 36.0 (12.4) 
Gender 
Females 20 (31.7) 24 (38.1) 
Males 43 (68.3) 39 (61.9) 
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Types of skin infections 
Infected wound 1 (1.6) 4 (6.3) 
Cellulitis 13 (20.6) 13 (20.6) 
Abscess 49 (77.8) 46 (73.0) 
 
Figure 1: Baseline demographic character gender 
 
Figure 2: Baseline demographic character age	
 
Figure 3: Types of skin infections 
Table 2: Early microbiological assessment 
Clinical responseeot 
(micro biology) 
Test group 
(n=63) 
Reference 
group (n=63) 
MRSA 18/20 12/15 
Streptococcus aureus 28/28 28/30 
Streptococcus py-
ogenes 9/9 9/12 
Streptococcus angi-
nosus 4/6 6/6 
Table 3: Clinical response microbiology 
Early clinical re-
sponse (micro biol-
ogy) 
Test group 
(n=63) 
reference 
group (n=63) 
MRSA 20/63 15/63 
Streptococcus aureus 28/63 30/63 
Streptococcus py-
ogenes 9/63 12/63 
Streptococcus angi-
nosus 6/63 6/63 
 
Figure 4: Early microbiological assessment	
 
Figure 5: Clinical Response Eot (Micro Biology)	
Table 4: Overall clinical response 
Clinical re-
sult 
Test 
group(n=63) 
Reference 
group(n=63) 
Clinical cure 56 (88.9) 51 (80.9) 
Clinical fail-
ure 7 (11.1) 12 (19.0) 
 
Figure 6: Overall clinical response	
Table 5: Adverse events reported 
Adverse effects 
reported 
Test 
group(n=63) 
Reference 
group(n=63) 
Decreased ap-
petite 1 2 
Dizziness 11 11 
Headache 5 10 
Insomnia 1 4 
Vomiting 2 2 
Increased bp 1 4 
Fatigue 3 5 
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Diarrhea 3 7 
 
Figure 7: Adverse events reported	
DISCUSSION	Total	 150	 subjects	were	 enrolled	 in	 the	 study	with	different	 types	 of	 skin	 infection,	 with	 MRSA	 re-sistance	infections.	All	the	subjects	were	explained	about	the	benefits	of	the	study.	Subjects	were	screened	according	to	the	in-clusive	 and	 exclusive	 criteria	 of	 the	 protocol	 de-signed.	Out	of	 150	patients,	 24	 subjects	were	with-drawn	or	dropped	out	from	the	study	due	to	lack	of	interest.	126	subjects	were	randomized	in	to	two	groups,	test	group	and	reference	group,	63	subjects	in	each	group.	The	patients	were	asked	to	sign	the	 inform	consent	forms.	Demographic	parameters	 like	age,	gender	were	col-lected	from	the	subjects	of	both	groups	in	the	case	re-pot	 forms.	 The	 microbiology	 that	 is	 presence	 of	MRSA,	streptococcus	species	in	blood	was	also	taken	into	consideration.	Both	 groups	 were	 given	 the	 drug	 treatment	 for	 7	days.	 On	 the	 day	 zero	 the	 ICF	 was	 collected	 from	them,	on	day-1	 the	drug	 treatment	was	 given.	 Sub-jects	were	asked	to	take	drug	once	daily	orally.		For	 the	 test	 group	 the	 IP	 was	 given,	 for	 reference	group	 linezolid	 400mg	 was	 given	 for	 7days.	 Both	groups	 subjects	were	 asked	 to	 take	 drug	 for	 seven	days	daily	once,	after	7	days	the	drug	treatment	was	stopped	 that	 is	 end	 of	 treatment.	 The	 clinical	 re-sponse	was	taken	from	subjects.	
Table 1	represents	the	baseline	demographic	charac-ters,	like	age,	gender,	types	of	infections	which	were	collected	 from	 subjects	 before	 the	 drug	 treatment	there	were	 20	 females	 and	 43	males	 from	 the	 test	group	and	24	females	and	39	males	were	enrolled	in	the	reference	group	they	are	represented	graphically	in	graph	no	1,	2	and	3.		There	were	three	types	of	skin	infections	reported	in	the	study	infected	wound	1	subject	in	test	group	and	4	from	the	test	group	were	reported,	cellulitis	1	sub-ject	and	13	from	reference	group	were	reported.	Ab-scess	49	in	test	group	and	46	in	reference	group.	Pre-sented	 in	 the	graph	no	3,	 there	were	more	patients	with	abscess	infection	in	both	groups.	
Table 2	presents	the	presence	of	microorganisms	in	the	blood	of	subjects	at	baseline,	there	were	MRSA	20	subjects	out	of	63	in	test	and	15	from	the	reference	groups,	 and	 there	 were	 streptococcus	 auresusann	other	micro	organism	in	the	blood,	before	treatment,	graphically	presented	in	graph	no	4.	
Table 3	presents	the	efficacy	of	the	drug,	the	reduc-tion	in	the	presence	of	microorganisms	in	the	blood,	after	 the	 drug	 treatment.	 Out	 of	 20	 subjects	 with	MRSA	resistance	18	subjects	showed	efficacy	in	test	and	12	out	of	15	from	reference	group,	and	strepto-coccousaureus	-28	out	of	28	responded	in	the	test	and	28	out	of	30	in	the	reference	group.	Streptococcus	pyogenes	-9	out	of	9	responded	in	the	test	 group	 ang	 9	 out	 of	 12	 responded	 in	 reference	group.	 Streptococcousanginosus	 –	 4	 out	 of	 6	 re-sponded	and	6	out	of	6	 responded	 in	 the	 reference	group.	This	is	presented	graphically	in	the	graph	no	5.	There	was	significant	response	for	the	test	drug.	
Table 4	presents	the	overall	clinical	response	in	both	groups.	Both	groups	responded	to	the	treatment,	the	clinical	cure	 for	7	days	treatment	 in	 test	group	was	88.9%	that	is	56	subjects	have	responded	and	51	sub-jects	(80%)	in	the	reference	group.	There	is	no	much	significant	 response	 in	 both	 groups.	 Test	 group	showed	better	efficacy.	The	clinical	failure	rate	was	11.1%	in	the	etest	group	that	 is	 7	 subjects,	 and	19%	 in	 the	 reference	 group.	The	reference	group	had	greater	clinical	failure	com-pared.	This	is	presented	in	the	graph	no	6.	
Table 5	 presents	 the	 safety	 evaluation:	 there	were	eight	 adverse	 effects	 reported	 in	 both	 group.	 Pre-sented	in	graph	no	7.	The	test	group	showed	greater	efficacy	and	safety	than	the	reference	group.	
CONCLUSION	The	study	was	conducted	in	omni	hospital,	dilsukhna-gar	for	a	period	of	6	months	in	the	finished	popula-tion.	 The	 incidence	 of	 drug-resistant	 Gram-positive	organisms	such	as	methicillin-resistant	Staphylococ-cus	aureus	 (MRSA)	has	 reached	a	point	where	new	therapeutic	options	are	urgently	needed.	The	results	suggest	tedizolid	phosphate	was	found	safe	and	effec-tive	than	linezolid	for	a	period	of	7	days	treatment	in	the	treatment	of	skin	infections.	
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